[1]李思瑶 钟江华.MicroRNA与心房颤动关系的研究进展[J].心血管病学进展,2020,(1):34-38.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.010]
　LI SiyaoZHONG Jianghua.The Relationship Between MicroRNA and Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2020,(1):34-38.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.010]
点击复制

MicroRNA与心房颤动关系的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2020年1期
页码:
34-38
栏目:
综述
出版日期:
2020-02-04

文章信息/Info

Title:
The Relationship Between MicroRNA and Atrial Fibrillation
作者:
李思瑶 钟江华
(中南大学湘雅医学院附属海口医院心血管内科,海南 海口 570208)
Author(s):
LI SiyaoZHONG Jianghua
(Cardiology Department,The Affiliated Haikou Hospital of Central South University Xiangya School of Medicine,Haikou People’s Hospital,Haikou 570208,Hannan,China)
关键词:
MicroRNA; 心房颤动; 机制; 心房电重构; 结构重构; 自主神经系统重构
Keywords:
MicroRNA; Atrial fibrillation; Mechanism; Atrial electrical remodeling; Structural reconstruction; Autonomic nervous system remodeling
DOI:
10.16806/j.cnki.issn.1004-3934.2020.01.010
摘要:
心房颤动是最常见的持续性心律失常，并有较高的发病率和死亡率。其流行率预计在未来几年会进一步增加。尽管在过去十年中出现了心房颤动病理生理学的新分子概念，但目前可用的治疗方法仍存在主要局限性，包括效果差和严重的副作用，如心室恶性心律失常等。心房电重构和结构重构、自主神经重构是心房颤动的发病基础，但驱动这种重构的确切机制仍不完全清楚。MicroRNA代表大量小非编码RNA的亚组，其降解或抑制其靶mRNA的翻译，从而调节基因表达并在广泛的生物学过程中起重要作用。临床上，越来越多的证据表明microRNA在心血管疾病的发生发展中发挥关键作用。
Abstract:
Atrial fibrillation is the most common persistent arrhythmia with high morbidity and mortality. Its prevalence is expected to increase further in the coming years.Although the new molecular concepts of AF pathophysiology have emerged during the last decade,the currently available therapeutic approaches have still major limitations including poor efficacy and serious side effects,such as malignant arrhythmias in the ventricle. Atrial electrical remodeling and structural remodeling ,autonomic nerve remodeling are the pathogenesis of atrial fibrillation ,but the exact mechanism driving this remodeling is still not fully understood. MicroRNAs represent a subgroup of small non-coding RNAs that degrade or inhibit the translation of their target mRNA,thereby regulating gene expression and playing an important role in a wide range of biological processes. Clinically,there is increasing evidence that microRNAs play a key role in the development of cardiovascular disease.

参考文献/References:

[1] Wijffels MC,Kirchhof CJ,Dorland R,et al. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats[J]. Circulation,1995,92:1954-1968.

[2] Iwasaki Y,Nishida K,Kato T,et al. Atrial fibrillation pathophysiology implications for management[J]. Circulation,2011,124(20):2264-2274.

[3] Hou Y,Zhou Q,Po SS. Neuromodulation for cardiac arrhythmia[J]. Heart Rhythm,2016,13(2):584-592.

[4] Lee RC,Feinbaum RL,Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14[J]. Cell,1993,75(5):843-854.

[5] Baetel DP. MicroRNAs:target recognition and regulatory functions[J]. Cell,2009,136(2):215-233.

[6] Molina CE,Voigt N. Finding Ms. or Mr. right:which miRNA to target in AF?[J]. J Mol Cell Cardiol,2017,102:22-25.

[7] Kakimoto Y,Tanaka M,Kamiguchi H,et al. MicroRNA deep sequencing reveals chamber-specific miR-208 family expression patterns in the human heart[J]. Int J Cardiol, 2016 ,211:43-48.

[8] Xiaomeng J,Shaohua Z,Xinxing X,et al. MicroRNA-1 accelerates the shortening of atrial effective refractory period by regulating KCNE1 and KCNB2 expression:an atrial tachypacing rabbit model[J]. PLoS One,2013,8(12):e85639.

[9] Zhao Y,Ransom JF,Li A,et al. Dysregulation of cardiogenesis,cardiac conduction,and cell cycle in mice lacking miRNA-1-2[J]. Cell,2007,129(2):303-317.

[10] Kumarswamy R,Lyon AR,Volkmann I,et al. SERCA2a gene therapy restores microRNA-1 expression in heart failure via an Akt/FoxO3A-dependent pathway[J]. Eur Heart J,2012,33(9):1067-1075.

[11] Chiang DY,Kongchan N,Beavers DL,et al. Loss of microRNA-106b-25 cluster promotes atrial fibrillation by enhancing ryanodine receptor type-2 expression and calcium release[J]. Circ Arrhythm Electrophysiol,2014,7(6):1214-1222.

[12] van den Berg NWE,Kawasaki M,Berger WR,et al. MicroRNAs in atrial fibrillation:from expression signatures to functional implications[J]. Cardiovasc Drugs Ther,2017,31(3):345-365.

相似文献/References:

[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
　HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
　DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
　ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(1):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
　ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(1):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
　HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(1):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
　WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(1):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
　XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(1):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
　ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(1):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[9]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
　WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(1):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[10]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
　ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(1):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]

更新日期/Last Update: 2020-03-23